Abstract
In vitro screening of thiacetazone derivatives indicated that two derivatives, SRI-286 and SRI-224, inhibited a panel of 25 Mycobacterium avium complex (MAC) isolates at concentrations of 2 micro g/ml or lower. In mice, SRI-224 and thiacetazone had no significant activity against the MAC in livers and spleens, but treatment with SRI-286 resulted in significant reduction of bacterial loads in livers and spleens. A combination of SRI-286 and moxifloxacin was significantly more active than single drug regimens in liver and spleen.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Anti-Bacterial Agents / therapeutic use*
-
Aza Compounds*
-
Colony Count, Microbial
-
Drug Therapy, Combination
-
Fluoroquinolones*
-
Humans
-
Liver / microbiology
-
Mice
-
Mice, Inbred C57BL
-
Microbial Sensitivity Tests
-
Moxifloxacin
-
Mycobacterium avium Complex*
-
Mycobacterium avium-intracellulare Infection / drug therapy*
-
Mycobacterium avium-intracellulare Infection / microbiology
-
Quinolines*
-
Spleen / microbiology
-
Thioacetazone / analogs & derivatives*
-
Thioacetazone / therapeutic use*
Substances
-
Anti-Bacterial Agents
-
Aza Compounds
-
Fluoroquinolones
-
Quinolines
-
SRI 224
-
SRI 286
-
Thioacetazone
-
Moxifloxacin